Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02927600
Other study ID # 15.18.NRC
Secondary ID
Status Completed
Phase N/A
First received September 14, 2016
Last updated November 9, 2017
Start date September 2016
Est. completion date October 2017

Study information

Verified date November 2017
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to determine which among high vs low Glycemic Index (GI) / Glycemic Responses (GR) interventions at breakfast or at dinner is the most effective for lowering glycemic response of the subsequent standard meal.


Description:

Consumption of low Glycemic Index (GI) foods has been shown to not only attenuate blood glucose response during the postprandial period immediately following a meal but to have also positive metabolic effects at the subsequent meal, known as the "second-meal effect" by reducing glucose excursion beyond actual meal. The relative importance of the timing of the glycemic load variation (e.g., breakfast or dinner) on the overall, 24h, glycemic control has not been investigated in detail.

We hypothesize that eating low GI foods in a single meal either for breakfast or for dinner would have different consequential effects on glycemic control over the following meal and thereafter during 24 hours. In order to establish the relative importance of breakfast or dinner in predicting glycemic control/response of the following meal and for a 24-hour period this study will use comprehensive methods including Continuous Glucose Monitoring Systems (CGMS) as well as measuring postprandial blood glucose and insulin.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria:

- Age = 50 to = 70 years old years

- Chinese male and female healthy subjects having both grandparents Chinese

- Body mass index: = 18.5 to = 24.9kg/m2

- Waist circumference =90 cm for males and = 85 cm for females

- Systolic blood pressure <150 mmHg; Diastolic blood pressure <90 mmHg

- Willing and able to sign written informed consent prior to trial entry

Exclusion Criteria:

- Known Diabetes type 2, under medication

- Fasting Glycemia > 7 mmol/L

- Any clinically relevant gastrointestinal (ulcer, malabsorption), renal (insufficiency), cardiovascular (stroke, arterial hypertension, heart disease), metabolic disease (dyslipidemia), psychiatric disorder (depression) that would affect the study in the opinion of the CNRC clinician, according to a detailed medical history and a blood sampling at screening, only if deemed necessary by CNRC clinician.

- Anemia (anamnesis)

- Subjects who had a history of major gastrointestinal surgery

- Subjects who had more than 5% weight loss from baseline weight during the past three months (more than 5% of initial weight)

- Present drug abuse or use of medications that could interfere with the treatment or energetic metabolism including corticosteroids, growth hormone, hormonal replacement therapy, anti-hypertensives like ACE inhibitor, thiazides and angiotensin receptors blockers. These conditions will be screened based on subject reporting. Participants will be asked to bring in their current medications at the time of screening, and these will be checked by the study-staff.

- Subject allergic /intolerant to any of the test foods or any of the following common food and ingredients: eggs, fish, milk, peanuts, and tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings etc.

- Subject on special diets especially vegetarian, high protein or weight loss program.

- Current smokers (i.e. people having smoked in the month preceding the enrolment)

- Subjects having a high alcohol consumption (more than 2 drinks/day)

- Subjects who are not willing and not able to comply with scheduled visits and the requirements of the study procedures in the opinion of the investigators.

- Currently participating or having participated in another clinical trial within 4 weeks prior to trial start.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Low GI Breakfast
Intake of low GI breakfast
High GI Breakfast
Intake of high GI breakfast
Low GI Dinner
Intake of Low GI dinner
High GI Dinner
Intake of high GI dinner

Locations

Country Name City State
Singapore Clinical Nutrition Research Center Singapore

Sponsors (2)

Lead Sponsor Collaborator
Nestlé Clinical Nutrition Research Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemia Incremental areas under curve (iAUC) of glycemia in the 3 hours following meal intake 3 hours
Secondary Glycemia Incremental areas under curve (iAUC) of glycemia over 24 hours 24h
Secondary Plasma glucagon Measure of plasma glucagon over a 3-h period following meal intake 3 hours
Secondary Plasma insulin Measure of plasma insulin over a 3-h period following meal intake 3 hours post meal intake
Secondary Plasma triglycerides Measure of plasma triglycerides over a 3-h period following meal intake 3 hours post meal intake
Secondary Plasma glycerol Measure of plasma glycerol over a 3-h period following meal intake 3 hours post meal intake
Secondary Plasma free fatty acids Measure of plasma free fatty acids over a 3-h period following meal intake 3 hours
Secondary Satiety Satiety will be assessed by Visual Analog Scales Every 30 minutes over the 3 hours post meal intake
Secondary Hunger Hunger will be assessed by Visual Analog Scales Every 30 minutes over the 3 hours post meal intake
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1